BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Riethdorf S, Soave A, Rink M. The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer. Transl Androl Urol 2017;6:1090-110. [PMID: 29354496 DOI: 10.21037/tau.2017.09.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Junker K. [Liquid biopsy to indvidualise therapy in advanced bladder cancer]. Aktuelle Urol 2022;53:180-7. [PMID: 34875700 DOI: 10.1055/a-1646-9568] [Reference Citation Analysis]
2 Honoré N, Galot R, van Marcke C, Limaye N, Machiels JP. Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact. Cancers (Basel) 2021;13:5364. [PMID: 34771526 DOI: 10.3390/cancers13215364] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Herranz R, Oto J, Plana E, Fernández-Pardo Á, Cana F, Martínez-Sarmiento M, Vera-Donoso CD, España F, Medina P. Circulating Cell-Free DNA in Liquid Biopsies as Potential Biomarker for Bladder Cancer: A Systematic Review. Cancers (Basel) 2021;13:1448. [PMID: 33810039 DOI: 10.3390/cancers13061448] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Luo H, Wei W, Ye Z, Zheng J, Xu RH. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends Mol Med 2021;27:482-500. [PMID: 33500194 DOI: 10.1016/j.molmed.2020.12.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
5 Hong M, He G, Goh S, Low AWX, Tay KJ, Lim TKH, Yeong J, Khor LY, Lim TS. Biomarkers for Precision Urothelial Carcinoma Diagnosis: Current Approaches and the Application of Single-Cell Technologies. Cancers (Basel) 2021;13:E260. [PMID: 33445605 DOI: 10.3390/cancers13020260] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Soave A, Kluwe L, Yu H, Rink M, Gild P, Vetterlein MW, Marks P, Sauter G, Fisch M, Meyer CP, Ludwig T, Dahlem R, Minner S, Pantel K, Steinbach B, Schwarzenbach H. Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy. Sci Rep 2020;10:21562. [PMID: 33298978 DOI: 10.1038/s41598-020-75869-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Rink M, Riethdorf S, Yu H, Kölker M, Vetterlein MW, Dahlem R, Fisch M, Pantel K, Soave A. The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy. J Clin Med 2020;9:E3478. [PMID: 33126664 DOI: 10.3390/jcm9113478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Agashe R, Kurzrock R. Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. Cancers (Basel) 2020;12:E2361. [PMID: 32825548 DOI: 10.3390/cancers12092361] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
9 Zhao C, Pan Y, Wang Y, Li Y, Han W, Lu L, Tang W, Li P, Ou Z, Zhang M, Xiong Z, Xu R, Lu Q, Xu Z, Qi L, Wang L, Xu G. A novel cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology for bladder cancer non-invasive detection in urine. Transl Androl Urol 2020;9:1222-31. [PMID: 32676405 DOI: 10.21037/tau-19-774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Bergmann S, Coym A, Ott L, Soave A, Rink M, Janning M, Stoupiec M, Coith C, Peine S, von Amsberg G, Pantel K, Riethdorf S. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). Oncoimmunology 2020;9:1738798. [PMID: 32391189 DOI: 10.1080/2162402X.2020.1738798] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
11 Powles T, Walker J, Andrew Williams J, Bellmunt J. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treatment Reviews 2020;82:101925. [DOI: 10.1016/j.ctrv.2019.101925] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
12 Wang D, Hu X, Long G, Xiao L, Wang ZM, Zhou LD. The clinical value of total plasma cell-free DNA in hepatitis B virus-related hepatocellular carcinoma. Ann Transl Med 2019;7:650. [PMID: 31930051 DOI: 10.21037/atm.2019.10.78] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
13 Kouba E, Cheng L. Clinical utility versus futility: a tipping point for liquid biopsies in bladder cancer. Future Oncol 2019;15:3751-3. [PMID: 31651200 DOI: 10.2217/fon-2019-0522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Kouba E, Lopez-Beltran A, Montironi R, Massari F, Huang K, Santoni M, Chovanec M, Cheng M, Scarpelli M, Zhang J, Cimadamore A, Cheng L. Liquid biopsy in the clinical management of bladder cancer: current status and future developments. Expert Rev Mol Diagn 2020;20:255-64. [PMID: 31608720 DOI: 10.1080/14737159.2019.1680284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
15 Tuaeva NO, Falzone L, Porozov YB, Nosyrev AE, Trukhan VM, Kovatsi L, Spandidos DA, Drakoulis N, Kalogeraki A, Mamoulakis C, Tzanakakis G, Libra M, Tsatsakis A. Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements. Cells 2019;8:E1251. [PMID: 31615102 DOI: 10.3390/cells8101251] [Cited by in Crossref: 29] [Cited by in F6Publishing: 37] [Article Influence: 9.7] [Reference Citation Analysis]
16 Kerr PS, Freedland SJ, Williams SB. The current status of molecular biomarkers in patients with metastatic urothelial carcinoma of the bladder. Expert Review of Molecular Diagnostics 2020;20:127-9. [DOI: 10.1080/14737159.2019.1665509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Rink M, Schwarzenbach H, Vetterlein MW, Riethdorf S, Soave A. The current role of circulating biomarkers in non-muscle invasive bladder cancer. Transl Androl Urol 2019;8:61-75. [PMID: 30976570 DOI: 10.21037/tau.2018.11.05] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Rink M, Schwarzenbach H, Riethdorf S, Soave A. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder. World J Urol 2019;37:1785-99. [DOI: 10.1007/s00345-018-2543-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
19 Lodewijk I, Dueñas M, Rubio C, Munera-Maravilla E, Segovia C, Bernardini A, Teijeira A, Paramio JM, Suárez-Cabrera C. Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring. Int J Mol Sci 2018;19:E2514. [PMID: 30149597 DOI: 10.3390/ijms19092514] [Cited by in Crossref: 30] [Cited by in F6Publishing: 42] [Article Influence: 7.5] [Reference Citation Analysis]
20 Maas M, Walz S, Stühler V, Aufderklamm S, Rausch S, Bedke J, Stenzl A, Todenhöfer T. Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer. Expert Review of Molecular Diagnostics 2018;18:443-55. [DOI: 10.1080/14737159.2018.1469979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]